Dr. Duval joined Certara in November 2017 with more than 15 years of experience in clinical pharmacology and pharmacometrics in drug development. Prior to joining Certara, Dr. Duval held different roles with both clinical pharmacology and pharmacometrics elements. In his last position, he was in charge of the clinical pharmacology components for the development, submission, and approval of oncology compounds within Novartis. Prior to that, he held a pharmacometrics position of growing responsibilities at Servier and Boehringer-Ingelheim.
Through his different roles and experiences Dr. Duval developed knowledge in both clinical pharmacology and pharmacometrics—two sides of the same coin: quantitative clinical pharmacology—by providing hands-on and strategic input to the teams. In his last position, he was leading a cross-functional teams providing clinical pharmacology input at the different stages of development for the respective programs. This contribution involved quantitative analysis, metabolism aspects, and clinical trials. The success of these teams was based the synergies across the different expertise (clinical pharmacology, statistics, pharmacometrics, medical sciences) to provide integrated quantitative support for the program at the different stages of the development.
Dr. Duval obtained a PharmD in Pharmacy at the University of Lyon and was initially exposed to the quantitative methods during his 4-year residency program under the supervision of Pr. Boissel and Dr. Girard and completed his knowledge in PK/PD modeling as post-doc in the PK/PD department at Uppsala University with Pr. Karlsson.